These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 10395849)

  • 21. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.
    Gulick RM; Mellors JW; Havlir D; Eron JJ; Gonzalez C; McMahon D; Richman DD; Valentine FT; Jonas L; Meibohm A; Emini EA; Chodakewitz JA
    N Engl J Med; 1997 Sep; 337(11):734-9. PubMed ID: 9287228
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nucleoside combinations for antiretroviral therapy: efficacy of stavudine in combination with either didanosine or lamivudine.
    Fisher M
    AIDS; 1998; 12 Suppl 3():S9-16. PubMed ID: 15168718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.
    Losso MH; Belloso WH; Emery S; Benetucci JA; Cahn PE; Lasala MC; Lopardo G; Salomon H; Saracco M; Nelson E; Law MG; Davey RT; Allende MC; Lane HC
    J Infect Dis; 2000 May; 181(5):1614-21. PubMed ID: 10823761
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
    Izopet J; Bicart-See A; Pasquier C; Sandres K; Bonnet E; Marchou B; Puel J; Massip P
    J Med Virol; 1999 Dec; 59(4):507-11. PubMed ID: 10534734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
    Ribera E; Rodríguez-Pardo D; Rubio M; Soler A; Pedrol E; Blanco JL; González A; Crespo M; Falcó V; Ocaña I; Deig E; Miró JM; Pahissa A
    Antivir Ther; 2005; 10(5):605-14. PubMed ID: 16152754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators.
    Kuritzkes DR; Marschner I; Johnson VA; Bassett R; Eron JJ; Fischl MA; Murphy RL; Fife K; Maenza J; Rosandich ME; Bell D; Wood K; Sommadossi JP; Pettinelli C
    AIDS; 1999 Apr; 13(6):685-94. PubMed ID: 10397563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients.
    Reliquet V; Ferré V; Hascoet C; Besnier JM; Bellein V; Arvieux C; Molina JM; Breux JP; Zucman D; Rozenbaum W; Allavena C; Raffi F;
    Antivir Ther; 1999; 4 Suppl 3():83-4. PubMed ID: 16021876
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tenofovir: new indication. For first-line antiretroviral therapy: wait and see.
    Prescrire Int; 2004 Oct; 13(73):180-2. PubMed ID: 15499699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients.
    Ungsedhapand C; Kroon ED; Suwanagool S; Ruxrungtham K; Yimsuan N; Sonjai A; Ubolyam S; Buranapraditkun S; Tiengrim S; Pakker N; Kunanusont C; Lange JM; Cooper DA; Phanuphak P
    J Acquir Immune Defic Syndr; 2001 Jun; 27(2):116-23. PubMed ID: 11404532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo antagonism with zidovudine plus stavudine combination therapy.
    Havlir DV; Tierney C; Friedland GH; Pollard RB; Smeaton L; Sommadossi JP; Fox L; Kessler H; Fife KH; Richman DD
    J Infect Dis; 2000 Jul; 182(1):321-5. PubMed ID: 10882616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Observational study on the efficacy of the application of two classical regimens of triple antiretroviral therapy].
    Eiros Bouza JM; Ortega Lafont M; Ortiz de Lejarazu R; Bachiller Luque P; de Luis Román DA
    An Med Interna; 2003 May; 20(5):239-42. PubMed ID: 12831297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party.
    Eron JJ; Benoit SL; Jemsek J; MacArthur RD; Santana J; Quinn JB; Kuritzkes DR; Fallon MA; Rubin M
    N Engl J Med; 1995 Dec; 333(25):1662-9. PubMed ID: 7477218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults.
    Raffi F; Reliquet V; Ferré V; Arvieux C; Hascoet C; Bellein V; Besnier JM; Breux JP; Garré M; May T; Molina JM; Perré P; Raguin G; Rozenbaum W; Zucman D
    Antivir Ther; 2000 Dec; 5(4):267-72. PubMed ID: 11142621
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial.
    Molina JM; Marcelin AG; Pavie J; Heripret L; De Boever CM; Troccaz M; Leleu G; Calvez V;
    J Infect Dis; 2005 Mar; 191(6):840-7. PubMed ID: 15717257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AVANTI 1: randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus loviride in HIV-infected antiretroviral-naive patients. AVANTI Study Group.
    Gatell J; Lange J; Gartland M
    Antivir Ther; 1999; 4(2):79-86. PubMed ID: 10682152
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
    Podzamczer D; Ferrer E; Consiglio E; Gatell JM; Perez P; Perez JL; Luna E; González A; Pedrol E; Lozano L; Ocaña I; Llibre JM; Casiró A; Aranda M; Barrufet P; Martínez-Lacasa J; Miró JM; Badía X; Casado A; Lupo S; Cahn P; Maños M; Estela J
    Antivir Ther; 2002 Jun; 7(2):81-90. PubMed ID: 12212928
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine.
    Plana M; Ferrer E; Martínez C; Podzamczer D; García F; Maleno MJ; Barceló JJ; García A; Barberá MJ; Lacarcel M; Miró JM; Gallart T; Gatell JM
    Antivir Ther; 2004 Apr; 9(2):197-204. PubMed ID: 15134181
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Focusing on the second phase of plasma HIV-1 RNA clearance.
    Lafeuillade A; Poggi C; Sayada C; Pellegrino P; Profizi N
    AIDS; 1997 Feb; 11(2):264-6. PubMed ID: 9030385
    [No Abstract]   [Full Text] [Related]  

  • 39. Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study.
    Henry K; Wallace RJ; Bellman PC; Norris D; Fisher RL; Ross LL; Liao Q; Shaefer MS;
    J Infect Dis; 2001 Feb; 183(4):571-8. PubMed ID: 11170982
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Virologic and CD4+ cell responses to new nucleoside regimens: switching to stavudine or adding lamivudine after prolonged zidovudine treatment of human immunodeficiency virus infection. ACTG 302 Study Team. AIDS Clinical Trials Group.
    Katzenstein DA; Hughes M; Albrecht M; Hammer S; Para M; Murphy R; Valdez H; Haubrich R; Liou S
    AIDS Res Hum Retroviruses; 2000 Jul; 16(11):1031-7. PubMed ID: 10933617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.